Cargando…

Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials

INTRODUCTION: Ventilator-associated pneumonia (VAP) is reported as the second most common nosocomial infection among critically ill patients with the incidence ranging from 2 to 16 episodes per 1000 ventilator days. The use of probiotics has been shown to have a promising effect in many RCTs. Our sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Batra, Priyam, Soni, Kapil Dev, Mathur, Purva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561245/
https://www.ncbi.nlm.nih.gov/pubmed/33082958
http://dx.doi.org/10.1186/s40560-020-00487-8
_version_ 1783595232049233920
author Batra, Priyam
Soni, Kapil Dev
Mathur, Purva
author_facet Batra, Priyam
Soni, Kapil Dev
Mathur, Purva
author_sort Batra, Priyam
collection PubMed
description INTRODUCTION: Ventilator-associated pneumonia (VAP) is reported as the second most common nosocomial infection among critically ill patients with the incidence ranging from 2 to 16 episodes per 1000 ventilator days. The use of probiotics has been shown to have a promising effect in many RCTs. Our systematic review and meta-analysis were thus planned to determine the effect of probiotic use in critically ill ventilated adult patients on the incidence of VAP, length of hospital stay, length of ICU stay, duration of mechanical ventilation, the incidence of diarrhea, and the incidence of oropharyngeal colonization and in-hospital mortality. METHODOLOGY: Systematic search of various databases (such as Embase, Cochrane, and Pubmed), published journals, clinical trials, and abstracts of the various major conferences were made to obtain the RCTs which compare probiotics with placebo for VAP prevention. The results were expressed as risk ratios or mean differences. Data synthesis was done using statistical software - Review Manager (RevMan) Version 5.4 (The Cochrane Collaboration, 2020). RESULTS: Nine studies met our inclusion criterion and were included in the meta-analysis. The incidence of VAP (risk ratio: 0.70, CI 0.56, 0.88; P = 0.002; I(2) = 37%), duration of mechanical ventilation (mean difference −3.75, CI −6.93, −0.58; P 0.02; I(2) = 96%), length of ICU stay (mean difference −4.20, CI −6.73, −1.66; P = 0.001; I(2) = 84%) and in-hospital mortality (OR 0.73, CI 0.54, 0.98; P = 0.04; I(2) = 0%) in the probiotic group was significantly lower than that in the control group. Probiotic administration was not associated with a statistically significant reduction in length of hospital stay (MD −1.94, CI −7.17, 3.28; P = 0.47; I(2) = 88%), incidence of oro-pharyngeal colonization (OR 0.59, CI 0.33, 1.04; P = 0.07; I(2) = 69%), and incidence of diarrhea (OR 0.59, CI 0.34, 1.03; P = 0.06; I(2) = 38%). DISCUSSION: Our meta-analysis shows that probiotic administration has a promising role in lowering the incidence of VAP, the duration of mechanical ventilation, length of ICU stay, and in-hospital mortality.
format Online
Article
Text
id pubmed-7561245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75612452020-10-16 Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials Batra, Priyam Soni, Kapil Dev Mathur, Purva J Intensive Care Review INTRODUCTION: Ventilator-associated pneumonia (VAP) is reported as the second most common nosocomial infection among critically ill patients with the incidence ranging from 2 to 16 episodes per 1000 ventilator days. The use of probiotics has been shown to have a promising effect in many RCTs. Our systematic review and meta-analysis were thus planned to determine the effect of probiotic use in critically ill ventilated adult patients on the incidence of VAP, length of hospital stay, length of ICU stay, duration of mechanical ventilation, the incidence of diarrhea, and the incidence of oropharyngeal colonization and in-hospital mortality. METHODOLOGY: Systematic search of various databases (such as Embase, Cochrane, and Pubmed), published journals, clinical trials, and abstracts of the various major conferences were made to obtain the RCTs which compare probiotics with placebo for VAP prevention. The results were expressed as risk ratios or mean differences. Data synthesis was done using statistical software - Review Manager (RevMan) Version 5.4 (The Cochrane Collaboration, 2020). RESULTS: Nine studies met our inclusion criterion and were included in the meta-analysis. The incidence of VAP (risk ratio: 0.70, CI 0.56, 0.88; P = 0.002; I(2) = 37%), duration of mechanical ventilation (mean difference −3.75, CI −6.93, −0.58; P 0.02; I(2) = 96%), length of ICU stay (mean difference −4.20, CI −6.73, −1.66; P = 0.001; I(2) = 84%) and in-hospital mortality (OR 0.73, CI 0.54, 0.98; P = 0.04; I(2) = 0%) in the probiotic group was significantly lower than that in the control group. Probiotic administration was not associated with a statistically significant reduction in length of hospital stay (MD −1.94, CI −7.17, 3.28; P = 0.47; I(2) = 88%), incidence of oro-pharyngeal colonization (OR 0.59, CI 0.33, 1.04; P = 0.07; I(2) = 69%), and incidence of diarrhea (OR 0.59, CI 0.34, 1.03; P = 0.06; I(2) = 38%). DISCUSSION: Our meta-analysis shows that probiotic administration has a promising role in lowering the incidence of VAP, the duration of mechanical ventilation, length of ICU stay, and in-hospital mortality. BioMed Central 2020-10-15 /pmc/articles/PMC7561245/ /pubmed/33082958 http://dx.doi.org/10.1186/s40560-020-00487-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Batra, Priyam
Soni, Kapil Dev
Mathur, Purva
Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials
title Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials
title_full Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials
title_fullStr Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials
title_full_unstemmed Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials
title_short Efficacy of probiotics in the prevention of VAP in critically ill ICU patients: an updated systematic review and meta-analysis of randomized control trials
title_sort efficacy of probiotics in the prevention of vap in critically ill icu patients: an updated systematic review and meta-analysis of randomized control trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561245/
https://www.ncbi.nlm.nih.gov/pubmed/33082958
http://dx.doi.org/10.1186/s40560-020-00487-8
work_keys_str_mv AT batrapriyam efficacyofprobioticsinthepreventionofvapincriticallyillicupatientsanupdatedsystematicreviewandmetaanalysisofrandomizedcontroltrials
AT sonikapildev efficacyofprobioticsinthepreventionofvapincriticallyillicupatientsanupdatedsystematicreviewandmetaanalysisofrandomizedcontroltrials
AT mathurpurva efficacyofprobioticsinthepreventionofvapincriticallyillicupatientsanupdatedsystematicreviewandmetaanalysisofrandomizedcontroltrials